{"disease":{"id":"factor-ix-inhibitors","name":"Factor IX inhibitors","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"fitusiran","indication_name":"Factor IX inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Qfitlia","generic_name":"FITUSIRAN","company_name":"Genzyme Corp","drug_phase":"marketed","molecular_target":"","drug_class":"Antithrombin-directed RNA Interaction [EPC]","quality_score":10,"revenue":"400","mechanism":"Qfitlia works by using small RNA molecules to block the production of antithrombin, a protein that can interfere with blood clotting."},{"drug_id":"hympavzi","indication_name":"Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia B (congenital factor IX deficiency) without factor IX inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"Marstacimab-Hncq","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)","drug_class":"Tissue Factor Pathway Inhibitor (TFPI) Antagonist","quality_score":65,"revenue":null,"mechanism":"Monoclonal antibody against TFPI Kunitz domain 2 to neutralize TFPI and enhance coagulation."},{"drug_id":"concizumab","indication_name":"hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alhemo","generic_name":"CONCIZUMAB","company_name":"Novo Nordisk Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Tissue Factor Pathway Inhibitor Antagonist [EPC]","quality_score":52,"revenue":null,"mechanism":"Alhemo works by blocking the activation of blood clotting factors to prevent excessive bleeding in people with hemophilia."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}